Marinus Pharmaceuticals drug Ztalmy is now FDA approved for treating the seizures in patients who have CDKL5 deficiency, an inherited form of epilepsy. The drug is the first approved treatment for the rare disorder and it’s also Marinus’s first approved product.
The company announced a contract with BARDA to develop intravenous ganaxolone for a seizure disorder that can result from exposure to nerve agents, in addition to announcing successful results from its Phase III trial of the oral version of the drug in a CDKL5 deficiency disorder, or CDD.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.